Securities code: Jafron Biomedical Co.Ltd(300529) securities abbreviation: Jafron Biomedical Co.Ltd(300529) Announcement No.: 2022045 bond Code: 123117 bond abbreviation: Jianfan convertible bond
Jafron Biomedical Co.Ltd(300529)
Announcement of the resolution of the 34th meeting of the 4th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of directors
Jafron Biomedical Co.Ltd(300529) (hereinafter referred to as “the company”) the 34th meeting of the Fourth Board of directors was held in the company’s conference room on April 13, 2022 in the form of on-site meeting and communication voting. 9 directors should attend the meeting, and 9 actually attended the meeting, which is in line with the relevant provisions of the company law and the company’s articles of association. The notice of this meeting was delivered to all directors by email and telephone on April 8, 2022.
Mr. Dong Fan, chairman of the company, convened and presided over the meeting, and the supervisors and senior managers of the company attended the meeting as nonvoting delegates. The convening of this board meeting complies with the relevant provisions of the company law and the articles of association.
2、 Deliberations of the board meeting
After careful discussion by the directors present at the meeting, the following proposals were considered and voted through:
1. The full text of the report for the first quarter of 2022 was considered and adopted
After deliberation, the board of Directors believes that the procedures for the company to prepare the full text of the first quarter report of 2022 comply with laws, regulations and the provisions of the CSRC; The contents of the report truly, accurately and completely reflect the actual situation of the company, and there are no false records, misleading statements or major omissions.
The full text of the company’s report for the first quarter of 2022 is published on cninfo.com, the gem information disclosure website designated by the CSRC on the same day（ http://www.cn.info.com.cn. ）Announcement.
Voting results: 9 in favor, 0 against and 0 abstention. The bill was passed.
It is hereby announced.
Jafron Biomedical Co.Ltd(300529) board of directors April 14, 2022
